ArticleJournal of clinical medicine2023

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease.

Marta Vernero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.